Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Case-Based Discussion

Program description

Join Dr. Moul and Dr. Morris, 2 tenured researchers and clinicians in the field of prostate cancer, as they discuss apalutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer. Through discussion of patient case studies, this webinar will highlight key data from the Phase 3 TITAN study and review the efficacy and safety data of apalutamide with ADT. Dr.'s Moul and Morris will also delve into subpopulation analyses and prostate-specific antigen kinetics from the TITAN study.

This webinar is sponsored by Janssen and is not a certified medical education program.

About the Presenters

Judd Moul, MD, FACS
James H. Semans, MD Professor of Surgery
Director of the Duke Prostate Center
Duke Cancer Institute at Duke University Medical Center

David Morris, MD, FACS
President and Co-Director
Advanced Therapeutics Center at Urology Associates

The speakers have received honoraria by Janssen.